Eli Lilly's anti-obesity pill, orforglipron, showed promising results in a new trial, achieving a 10.5% average weight loss in overweight individuals with diabetes. This follows an earlier trial showing a 12.4% weight loss in participants without diabetes, though slightly below expectations. The results boost Lilly's plans to seek FDA approval, intensifying competition with Novo Nordisk. An oral weight-loss pill would be cheaper to produce than injectable versions, increasing market potential. Despite some investor concerns following the initial trial results, Lilly executives made significant stock purchases, signaling confidence in the drug's future.

Prepared by Olivia Bennett and reviewed by editorial team.